A 3D biomimetic liver sinusoid construct for predicting physiology and toxicity

用于预测生理学和毒性的 3D 仿生肝正弦结构

• 批准号: 8516131
• 负责人: D. Lansing Taylor
• 金额: $ 104.63万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-24 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516131
• 关键词: 3-Dimensional; Accounting; Address; Albumins; Ammonia; Animal Model; Animal Testing; Bile Acids; Biochemical; Bioinformatics; Biological Assay; Biomimetics; Biosensor; Blood; Blood Coagulation Factor; Cell Fraction; Cell Respiration; Cell Survival; Cell physiology; Cells; Chemical Industry; Cholesterol; Clinical; Clinical Data; Clinical Trials; Coculture Techniques; Cytochrome P450; Data; Databases; Discontinuous Capillary; Disease model; Distant; Drug Interactions; Drug Metabolic Detoxication; Drug Targeting; Drug usage; Endothelial Cells; Engineering; Failure; Fibrinogen; Fluorescent Probes; Gene Expression; Gluconeogenesis; Glucose; Glutathione; Glycolysis; Goals; Hepatobiliary; Hepatocyte; Hepatotoxicity; Heterogeneity; Homeostasis; Human; Human body; In Vitro; Kupffer Cells; Life; Liver; Mass Spectrum Analysis; Metabolic; Metabolic Biotransformation; Microfluidic Microchips; Microfluidics; Modeling; Monitor; Organ; Organ Model; Oxygen; Pattern; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase I Clinical Trials; Physiology; Play; Population; Reading; Role; Safety; Self Care; Sentinel; Series; Staging; System; Time; Tissue Viability; Toxic effect; Toxin; Urea; Validation; Viral; Work; Xenobiotics; base; cell growth; cell type; cellular transduction; clinical efficacy; design; drug candidate; drug development; drug discovery; drug efficacy; drug metabolism; efficacy testing; exposed human population; fatty acid oxidation; hepatic acinus structure; improved; in vitro Assay; in vitro Model; in vivo; liver function; predictive modeling; public health relevance; response; safety testing; stellate cell; tool; 3-Dimensional; Accounting; Address; Albumins; Ammonia; Animal Model; Animal Testing; Bile Acids; Biochemical; Bioinformatics; Biological Assay; Biomimetics; Biosensor; Blood; Blood Coagulation Factor; Cell Fraction; Cell Respiration; Cell Survival; Cell physiology; Cells; Chemical Industry; Cholesterol; Clinical; Clinical Data; Clinical Trials; Coculture Techniques; Cytochrome P450; Data; Databases; Discontinuous Capillary; Disease model; Distant; Drug Interactions; Drug Metabolic Detoxication; Drug Targeting; Drug usage; Endothelial Cells; Engineering; Failure; Fibrinogen; Fluorescent Probes; Gene Expression; Gluconeogenesis; Glucose; Glutathione; Glycolysis; Goals; Hepatobiliary; Hepatocyte; Hepatotoxicity; Heterogeneity; Homeostasis; Human; Human body; In Vitro; Kupffer Cells; Life; Liver; Mass Spectrum Analysis; Metabolic; Metabolic Biotransformation; Microfluidic Microchips; Microfluidics; Modeling; Monitor; Organ; Organ Model; Oxygen; Pattern; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase I Clinical Trials; Physiology; Play; Population; Reading; Role; Safety; Self Care; Sentinel; Series; Staging; System; Time; Tissue Viability; Toxic effect; Toxin; Urea; Validation; Viral; Work; Xenobiotics; base; cell growth; cell type; cellular transduction; clinical efficacy; design; drug candidate; drug development; drug discovery; drug efficacy; drug metabolism; efficacy testing; exposed human population; fatty acid oxidation; hepatic acinus structure; improved; in vitro Assay; in vitro Model; in vivo; liver function; predictive modeling; public health relevance; response; safety testing; stellate cell; tool

DESCRIPTION (provided by applicant): A 3D biomimetic liver sinusoid construct for predicting physiology and toxicity Approximately 90% of drug candidates entering Phase 1 clinical trials fail, and one of the main reasons for drug failure is unexpected toxicity. The liver plays a centra role in the human body, contributing to homeostasis and important functions such as biotransformation and metabolism of drugs. The liver is also the most common target for drug-induced toxicity. Existing in vitro models and in vivo animal models have limited predictive power for human liver toxicity. The goal of this project is to construct a microfluidic liver modul which mimics the functions and responses of the human liver, with readouts designed to indicate both normal liver function and toxic responses. This human liver model is expected to be the essential elimination organ for modeling human exposure, provide improved predictions of drug induced liver toxicity, and also serve as a disease model for drug discovery. Our approach will be to develop a 3D microfluidic system with human hepatocyte, kupffer, stellate and endothelial cells, to mimic the liver acinus - the smallest functional unit of the liver. A uniue feature of the model will be the oxygenation of the media, and the establishment of an oxygen gradient, which is believed to account for important metabolic, gene expression and functional heterogeneity of the hepatocytes in the sinusoidal space of normal human liver. Hepatocytes in the oxygen rich zone are efficient in oxidative metabolism, fatty acid oxidation, gluconeogenesis, bile acid extraction, ammonia detoxification to urea and glutathione-conjugation while hepatocytes in the oxygen depleted zone are efficient in glycolysis, liponeogenesis and Cytochrome P-450 biotransformation. Another unique feature of the model will be the incorporation of 'sentinel' biosensor cells, a small fraction of cells with engineered biosensors that indicate changes in cellular functions. When combined with other fluorescent probes, standard biochemical and mass spectroscopy readouts, the model will provide a real-time High Content Analysis (HCA) profile to monitor organ function and response. The selection and validation of readouts and performance of the model will be evaluated based on a panel of reference drugs with available clinical data. To facilitate that comparison, a database of drugs with clinical data, and data from other in vitro and in vivo studies will be constructed. The ultimate goal of this project is to develop a microfluidic model of human liver function that will integrate with a series of other human organ modules, to create a microphysiology platform that reproduces human clinical trial results and provides improved predictivity of exposure, safety and efficacy for drug development. The liver plays a central role in human drug interactions, both within the liver and in other organs, as a result of drug metabolism. The performance of the liver module is central to the performance of the microphysiology platform. We believe the design proposed here will optimally recapitulate human liver function on that platform.

描述（由申请人提供）：一种3D仿生肝正弦构建体，用于预测生理学和毒性的大约90％的候选药物进入1期临床试验失败，而药物衰竭的主要原因之一是意想不到的毒性。肝脏在人体中起着中心作用，有助于体内平衡和重要功能，例如药物的生物转化和代谢。肝脏也是药物诱导毒性的最常见靶标。现有的体外模型和体内动物模型对人肝毒性的预测能力有限。该项目的目的是构建一个微流体肝模块，该微流体模拟人类肝脏的功能和反应，旨在指示正常肝功能和有毒反应的读数。预计这种人肝模型将是建模人类暴露，提供改进的药物诱导肝毒性的预测，并作为药物发现疾病模型的预测。 我们的方法是开发一个具有人类肝细胞，库普弗，星状和内皮细胞的3D微流体系统，以模仿肝脏 - 肝脏 - 肝脏的最小功能单位。该模型的一个统一特征将是培养基的氧合，以及建立氧梯度，氧气梯度据信可以解释正常人肝脏正弦空间中肝细胞的重要代谢，基因表达和功能异质性。富含氧的肝细胞在氧化代谢，脂肪酸氧化，糖异构，胆汁酸提取，氨基酸提取，氨基酸排毒对尿素和谷胱甘肽偶联的过程中有效，而氧气中的肝细胞则有效地在糖氧化和糖化症中有效。该模型的另一个独特特征将是掺入“前哨”生物传感器细胞，这是一小部分带有工程生物传感器的细胞，表明细胞功能的变化。当与其他荧光探针（标准的生化和质谱读数）结合使用时，该模型将提供实时高含量分析（HCA）曲线以监视器官功能和响应。将根据具有可用临床数据的参考药物小组评估读数和验证模型的验证和性能。为了促进该比较，将构建具有临床数据的药物数据库，以及其他体外和体内研究的数据。 该项目的最终目标是开发人类肝功能的微流体模型，该模型将与一系列其他人体器官模块整合，以创建一个微生物生理学平台，该平台可再现人类的临床试验结果，并提高了对药物开发的暴露，安全性和有效性的预测性。由于药物代谢，肝脏在肝脏和其他器官内的人类药物相互作用中起着核心作用。肝模块的性能对于微生物生理平台的性能至关重要。我们认为，这里提出的设计将在该平台上最佳地概括人肝功能。